Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPE | Q05469 | 8/20 | 0.37 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.37 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.37 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.35 |
| ▸ | LPL | P06858 | 1/20 | 0.35 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.35 |
| ▸ | P4HB | P07237 | 1/20 | 0.35 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.34 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31689032 | 1.00 | LIPE (0.37) | LIPEUSP30AAK1DGAT1ADRA1A | |
| SCHEMBL9986523 | 0.83 | LMNA (0.47) | — | |
| SCHEMBL22315885 | 0.82 | LPL (0.37) | LIPEDGAT1LPLLIPGP4HB | |
| SCHEMBL20607823 | 0.82 | LIPE (0.38) | LIPEDGAT1LPLLIPGP4HB | |
| SCHEMBL16426147 | 0.82 | PRMT5 (0.43) | USP30AAK1DGAT1LPLLIPG | |
| SCHEMBL5841748 | 0.82 | AAK1 (0.37) | LIPEUSP30AAK1DGAT1PRMT5 | |
| SCHEMBL16429522 | 0.81 | AAK1 (0.34) | LIPEUSP30AAK1DGAT1PRMT5 | |
| SCHEMBL29453753 | 0.79 | TSHR (0.57) | — | |
| SCHEMBL11662 | 0.79 | TSHR (0.57) | — | |
| SCHEMBL28950656 | 0.79 | USP30 (0.37) | USP30AAK1DGAT1ADRA1AADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250313572-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC (US) | 2025-10-09 | — | — | US | disclosed |
| US-20240228509-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC (US) | 2024-07-11 | — | — | US | disclosed |
| US-11976083-B2 | Inhibitors of peptidylarginine deiminases | GILEAD SCIENCES, INC. (US) | 2024-05-07 | — | — | US | disclosed |
| CN-115551862-B | Macrocyclic inhibitors of peptidyl arginine deiminase | 吉利德科学公司 | 2024-04-12 | — | — | CN | disclosed |
| US-20230399340-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC (US) | 2023-12-14 | — | — | US | disclosed |
| EP-3740478-B1 | FUSED IMIDAZOLE DERIVATIVES AS IL-17 MODULATORS | UCB Biopharma SRL (BE) | 2023-11-01 | — | — | EP | disclosed |
| EP-4143189-A1 | MACROCYCLIC INHIBITORS OF PEPTIDYLARGININE DEIMINASES | GILEAD SCIENCES, INC. (US) | 2023-03-08 | — | — | EP | disclosed |
| US-20230002412-A1 | INHIBITORS OF PEPTIDYLARGININE DEIMINASES | GILEAD SCIENCES, INC. | 2023-01-05 | — | — | US | disclosed |
| CN-115551862-A | Macrocyclic inhibitors of peptidyl arginine deiminase | 吉利德科学公司 | 2022-12-30 | — | — | CN | disclosed |
| US-11472794-B2 | Fused imidazole derivatives as IL-17 modulators | UCB Biopharma SRL (BE) | 2022-10-18 | — | — | US | disclosed |
| US-20170088526-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-03-30 | — | — | US | disclosed |
| US-20170088526-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-03-30 | — | — | US | disclosed |
| US-9499487-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-11-22 | — | — | US | disclosed |
| US-9499487-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-11-22 | — | — | US | disclosed |
| US-20120309724-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2012-12-06 | — | — | US | disclosed |
| US-20120309724-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2012-12-06 | — | — | US | disclosed |
| WO-2012166390-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2012-12-06 | — | — | WO | disclosed |
| EP-1549632-A4 | NOVEL THIOPHENE AMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS | DIMENSIONAL PHARM INC (US) | 2005-11-09 | — | — | EP | disclosed |
| EP-1549632-A1 | NOVEL THIOPHENE AMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2005-07-06 | — | — | EP | disclosed |
| WO-2003099805-A1 | NOVEL THIOPHENE AMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309724-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | LIPE 1620/4885USP30 1810/4885AAK1 3015/4885 |
| US-20240228509-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | MCL1, BCL2A1, BCL2L10 | LIPE 4722/4885USP30 1371/4885AAK1 1879/4885 |
| US-11472794-B2 | Fused imidazole derivatives as IL-17 modulators | IL17A, IL2, IL23R | LIPE 4425/4885USP30 1627/4885AAK1 2070/4885 |
| US-11976083-B2 | Inhibitors of peptidylarginine deiminases | PADI4, PADI2, PADI1 | LIPE 1114/4885USP30 967/4885AAK1 4188/4885 |
| US-20250313572-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | MCL1, BCL2A1, BCL2L10 | LIPE 4722/4885USP30 1371/4885AAK1 1879/4885 |
| US-20230002412-A1 | INHIBITORS OF PEPTIDYLARGININE DEIMINASES | PADI4, PADI2, PADI1 | LIPE 1114/4885USP30 967/4885AAK1 4188/4885 |
| US-20170088526-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | LIPE 1620/4885USP30 1810/4885AAK1 3015/4885 |
| US-20230399340-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | MCL1, BCL2A1, BCL2L10 | LIPE 4722/4885USP30 1371/4885AAK1 1879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.